Extrachromosomal DNA, circular DNA molecules separate from the chromosomes, are notorious for harboring oncogenes that fuel cancer progression. Unlike chromosomal DNA, ecDNAs replicate and segregate imperfectly during cell division, often resulting in their rapid loss from daughter cells. Until now, the processes that ensure ecDNA retention and amplification despite this challenge remained poorly understood, limiting our grasp of cancer biology at a genomic level.

The team employed advanced evolutionary simulations to dissect the interplay between ecDNA retention fidelity and natural selection in the context of tumor cell populations. Their models revealed that ecDNAs could only achieve significant amplification when the fidelity of their retention during mitosis exceeded 90%. If retention rates dropped below this threshold, even potent selective advantages conferred by oncogenes failed to stabilize ecDNA presence, highlighting that near-perfect mitotic retention is essential for ecDNA-driven oncogenic expansion.

Intriguingly, this theoretical minimum retention rate mirrored experimental observations garnered through cutting-edge live-cell imaging. A single retention element embedded within ecDNAs was sufficient to confer a roughly 10% failure rate per mitosis, confirming the simulation predictions. This tight correlation underscores the biological importance of retention elements in sustaining the oncogenic functions of ecDNA lineages within tumors.

Further analyses of patient tumor samples revealed that nearly all ecDNA amplicons containing oncogenes also carried retention elements, with 98% co-amplification observed. These retention elements frequently co-localized with oncogenes on large ecDNA segments often exceeding one megabase in size, vastly larger than the oncogene sequences themselves. This excess DNA likely harbors multiple retention elements, collectively enhancing mitotic stability and promoting persistent oncogene expression.

Contrastingly, linear chromosomal amplifications displayed more variable sizes and a sparser distribution of retention elements, suggesting a fundamental difference in how ecDNA and chromosomal amplifications evolve and maintain themselves in cancer cells. DNA segments lacking retention elements were commonly linked to those with retention elements on ecDNAs, but such associations were absent in linear amplifications, reinforcing the specific structural significance of retention elements for extrachromosomal maintenance.

Investigating spatial patterns, the study found that the local density of retention elements inversely correlated with ecDNA amplicon size. Genomic regions rich in retention elements tended to give rise to smaller ecDNA circles, whereas low-density areas favored larger ecDNA amplicons to encompass at least one retention element. This nuanced relationship influences the architecture of ecDNA and indicates that cancer cells exploit retention element distribution to optimize oncogene amplification efficiently.

Beyond tumor contexts, the researchers also explored the presence of retention elements in smaller, nonclonal extrachromosomal circular DNAs—known as microDNAs—which are prevalent in normal somatic tissues but typically not amplified. Remarkably, although most microDNAs lacked retention elements, there was a significant enrichment of these elements within microDNAs compared to random genomic segments across diverse human cell lines, implicating retention elements even in the persistence of small circular DNAs outside cancerous settings.

Epigenetic profiling of retention elements demonstrated lower DNA methylation levels compared to matched genomic intervals, suggesting a unique chromatin environment that might favor retention element function. Targeted methylation of retention elements using CRISPRoff technology reduced ecDNA tethering within cells, highlighting the critical role of their epigenetic state in maintaining ecDNA stability.

Functionally, these findings converge on a model in which retention elements serve as molecular anchors securing ecDNA during mitosis, thereby enhancing their inheritance and enabling sustained oncogene-driven proliferation. This synergy between retention and selection fundamentally shapes ecDNA-driven tumor evolution and offers promising targets for disrupting the oncogenic potential of extrachromosomal genetic material.

The implications are profound: targeting retention elements or their associated molecular machinery could destabilize ecDNA maintenance, leading to loss of oncogene amplification and potentially sensitizing tumors to existing therapies. This strategy opens a new frontier in cancer treatment, focused on extrachromosomal genetic regulation rather than chromosomal mutations alone.

In conclusion, this study elucidates how genetic retention elements are central to the selective amplification and persistence of oncogene-containing ecDNAs in cancer. By bridging computational modeling, patient-derived genomic data, and epigenetic analyses, the work paints a comprehensive picture of extrachromosomal DNA biology with far-reaching consequences for cancer research and therapy development.

Subject of Research:
Retention elements that facilitate the maintenance and selective amplification of oncogene-containing extrachromosomal DNA in cancer cells.

Article Title:
Genetic elements promote retention of extrachromosomal DNA in cancer cells.

Article References:
Sankar, V., Hung, K.L., Gnanasekar, A. et al. Genetic elements promote retention of extrachromosomal DNA in cancer cells. Nature (2025). https://doi.org/10.1038/s41586-025-09764-8

DOI:
https://doi.org/10.1038/s41586-025-09764-8

B-ALL is a pernicious cancer characterized by an overproduction of immature B-cells, a vital component of the immune system responsible for antibody production. These malignant cells proliferate within the bone marrow, crowding out healthy blood cells and disseminating to other organs, including the brain, where they can evade conventional therapies. The disease commonly afflicts children, accounting for about 40% of all childhood cancers, but it also affects adults, in whom treatment outcomes are typically poorer.

Current standard-of-care approaches for B-ALL involve lengthy and intensive chemotherapy protocols spanning over two years, which, while often effective in younger patients, carry profound toxicities. Patients endure severe side effects such as immunosuppression leading to infections, bruising, bleeding, nausea, hair loss, and long-term complications affecting the nervous system, joints, and cardiac function. Alternative therapies like bone marrow transplants and CAR-T cell therapy have emerged but present their own challenges, including severe side effects, high costs, and complex logistics.

In a paper published in Nature Communications, a team led by Dr. Simon Richardson and Professor Brian Huntly has unveiled a promising new strategy employing a combination of two oral agents: venetoclax and inobrodib. Venetoclax, already approved for a related blood malignancy, acute myeloid leukemia (AML), functions by inhibiting the BCL2 protein, a key regulator of apoptosis or programmed cell death in cancerous B-cells. However, venetoclax alone shows inconsistent effectiveness against B-ALL, prompting researchers to explore mechanisms underlying resistance.

Their investigations centered on the CREBBP gene, which when mutated or inactivated, contributes to disease progression and chemotherapy resistance. CREBBP plays a crucial role in cellular metabolism and gene expression regulation. Astonishingly, the team discovered that inactivating CREBBP rewires the fat metabolism pathways within malignant B-cells. This metabolic shift sensitizes cells to death by ferroptosis — a form of programmed cell death distinct from apoptosis. Ferroptosis involves the iron-dependent peroxidation of lipids in cell membranes, which, when unchecked, leads to catastrophic cellular damage and demise.

To exploit this vulnerability, the Cambridge researchers utilized inobrodib, an inhibitor of CREBBP developed by CellCentric, a Cambridge spinout company. Through CREBBP inhibition with inobrodib, the cancer cells undergo metabolic rewiring that diminishes their ability to prevent lipid damage. When combined with venetoclax’s blockade of BCL2, this dual insult induces ferroptotic cell death in B-ALL cells, including those harboring mutations that confer resistance to venetoclax alone.

Experimental models using human and mouse B-ALL cells demonstrated that this combination therapy powerfully eradicated malignant early-stage B-cells. Notably, the therapy maintained effectiveness against genetically resilient leukemia cells, highlighting its potential to overcome existing treatment barriers. Professor Huntly emphasized the significance of these findings, noting that venetoclax and inobrodib have been safely combined in early trials for AML, bolstering hopes for rapid translation into clinical trials for B-ALL patients.

This therapeutic innovation carries several clinical advantages. Because the drugs are administered orally, the treatment paradigm could be less invasive and more convenient than current protocols. Moreover, the selective targeting of cancerous B-cells with this approach suggests fewer off-target effects, potentially sparing patients the debilitating toxicities commonly associated with chemotherapy and immunotherapies like CAR-T cells—the latter of which can irreversibly deplete normal B-cell populations, impairing immune competence.

Dr. Richardson elaborated on the immune implications, explaining that although B-cells are depleted during administration, the body’s capacity to regenerate healthy B-cells should restore immune function post-treatment. This transient effect markedly contrasts with permanent B-cell aplasia seen in CAR-T cell therapies, making venetoclax and inobrodib a potentially safer therapeutic option.

An important economic consideration accompanies this therapeutic prospect. Venetoclax’s patent expiration in the near future is anticipated to reduce its cost substantially through generics, improving accessibility and affordability for patients and healthcare systems alike. Such developments could democratize use and alleviate financial burdens associated with novel cancer therapies.

The urgency for improved B-ALL therapies is underscored by the real-life experience of survivors like Gill Murphy, who endured aggressive chemotherapy and stem cell transplant for her disease. Her story reveals the profound physical and psychological toll of current treatments, including prolonged hospitalizations and enduring side effects such as fatigue, early menopause, and cognitive challenges. Murphy’s testimony provides a poignant backdrop for the pressing need to develop more tolerable and effective treatments.

Cancer researchers have long sought strategies that not only eliminate malignant cells but also minimize collateral damage to patients’ quality of life. The Cambridge team’s discovery of ferroptosis induction via CREBBP inactivation, combined with BCL2 inhibition, represents a breakthrough in this quest. By harnessing the cancer cell’s metabolic liabilities, this approach exploits a previously untapped cell death pathway, broadening therapeutic horizons.

Despite the promising preclinical data, rigorous clinical trials are essential before this dual-drug approach can become standard treatment. The researchers are actively pursuing funding to initiate clinical trials involving adults and teenagers with B-ALL. Success in these trials could herald a new era of cancer treatment that balances efficacy with safety and patient well-being.

Beyond B-ALL, this research might also illuminate the role of ferroptosis in other hematologic malignancies and solid tumors, inspiring novel drug combinations that trigger ferroptotic cell death in resistant cancers. As scientists deepen understanding of cancer metabolism and cell death pathways, such targeted treatments could transform oncological care globally.

In conclusion, the combination of venetoclax and inobrodib leverages cutting-edge insights into genetic mutations and metabolic reprogramming to strike at the heart of B-ALL survival mechanisms. Its promise lies not only in potentially overcoming drug resistance but in offering a gentler, more precise treatment pathway that could improve survival while mitigating the physical and emotional burdens endured by patients. As research progresses, hopes rise for a future where blood cancers like B-ALL are not just treatable but conquered with compassion and precision.

Subject of Research: Animals

Article Title: CREBBP inactivation sensitizes B cell Acute Lymphoblastic Leukemia to Ferroptotic Cell Death upon BCL2 Inhibition

News Publication Date: 20-May-2025

Web References: 10.1038/s41467-025-59531-6

References: Garcia-Gimenez, A, et al. CREBBP inactivation sensitizes B cell Acute Lymphoblastic Leukemia to Ferroptotic Cell Death upon BCL2 Inhibition. Nat Comms; 20 May 2025; DOI: 10.1038/s41467-025-59531-6

Keywords: Blood cancer, Leukemia, Cancer

Appalachia, which spans 423 counties across 13 states, encompassing more than 26 million residents, is known for its picturesque landscapes and deep-rooted folk culture. However, this region has also been marked by significant health disparities, particularly concerning cancer care. The authors of this study recognized that previous research often treated Appalachia as a homogeneous entity. In reality, the region is a tapestry of diverse counties, each with its unique socio-economic landscapes and healthcare access challenges. By delving into this granularity, the researchers aimed to illuminate the stark differences in cancer experiences across various Appalachian communities.

There is an important distinction in cancer trends across Appalachia. Certain areas, particularly those in Central Appalachia, show alarmingly high rates of cancer incidence and mortality. Research indicates that these disparities are exacerbated in regions with significant historical ties to coal mining and other hazardous industries, contributing to higher exposure risks. This complexity necessitates an understanding of the environmental and occupational factors influencing health outcomes. Moreover, high poverty rates and limited healthcare access have compounded these issues, creating an urgent need for improved public health infrastructure.

Key data from the study reveals that, from 2017 to 2021, those living in Appalachia were 5.6% more likely to receive a cancer diagnosis. This disparity translates into a staggering 12.8% increase in the likelihood of succumbing to cancer compared to individuals outside the region. The authors emphasize that although screening initiatives have made headway in certain demographics, the frequency of deaths from preventable cancers remains unduly high in Appalachia. This is particularly concerning for cancers that are amenable to early detection — including breast, cervical, and colorectal cancers — underscoring the need for heightened awareness and targeted screening efforts.

Despite significant healthcare progress in other parts of the country, the Appalachian region has seen only marginal improvements in cancer outcomes. While the overall rates of cancer incidence and mortality are declining — by 0.33% and 1.39%, respectively — these decreases lag behind those observed in regions outside Appalachia. This discrepancy evokes a broader discussion regarding healthcare equity and the need for tailored public health campaigns that account for the unique challenges faced by Appalachian populations.

In terms of emergent cancer trends, this study brought to light concerning increases in liver cancer and late-stage cervical cancer. Data from 2004 to 2021 indicates that liver cancer diagnoses have surged by approximately 3.77% annually, nearly double the rate of increase outside Appalachian boundaries. These trends warrant attention, especially as they are often linked to underlying health issues, such as the prevalence of hepatitis C within affected communities. Concurrently, the rising rates of late-stage cervical cancer highlight the critical need for enhanced screening and public education on preventative measures.

Spearheading these findings, the research team — led by Todd Burus, a data scientist affiliated with the Markey Cancer Center — advocates for a localized approach to healthcare. The notion that all Appalachian communities share a common experience with cancer is erroneous. Instead, careful segmentation and focused outreach programs are essential. Understanding the unique dynamics of each subregion allows healthcare practitioners and policymakers to design interventions that more effectively combat these disparities.

Furthermore, the intersection of behavioral health factors such as smoking, obesity, and insufficient HPV vaccination rates further complicates the cancer landscape in Appalachia. Previous studies have illustrated how these lifestyle choices correlate with increased cancer risks, reinforcing the imperative for comprehensive health initiatives that encompass nutrition, exercise, smoking cessation, and vaccination campaigns.

In light of these findings, researchers have expressed optimism about the future of cancer care in Appalachia. By employing targeted strategies, such as increased mobile screening units and community outreach programs tailored to local demographics, it is possible to make a significant impact on cancer outcomes. Recent public health initiatives have demonstrated the potential of such interventions, as evidenced by an uptick in lung cancer screenings in Kentucky that surpassed national averages. Outcomes in lung cancer death rates have shown marked improvement due to these proactive measures, proving that systemic change is possible.

As the study reflects, there are pathways to mitigate these disparities. Central to this endeavor is collaboration among healthcare providers, community organizations, and policymakers to ensure equitable access to preventive care. By disseminating findings from in-depth research endeavors like this study, it becomes feasible to empower at-risk populations and advocate for the necessary systemic changes that facilitate health equity.

This examination sheds light on the enduring cancer crisis in Appalachia while also emphasizing the wealth of knowledge that can emerge from specialized studies. The ongoing narrative of cancer in Appalachia is complex but not unchangeable. Each insight generated through meticulous research presents a chance to rethink and reshape how communities approach cancer care.

As Appalachia continues to grapple with its health challenges, the commitment to research and integrated health solutions remains paramount. Encouraging public dialogue surrounding cancer awareness, prevention, and the importance of early screening will be critical in changing the prevailing narrative across this storied region. With sustained efforts, the journey toward reduced cancer disparities can transition from a hopeful aspiration to a tangible reality.

Subject of Research: People
Article Title: Examining Geographic Disparity: Variation in Cancer Outcomes within Appalachia
News Publication Date: 6-Feb-2025
Web References: DOI Link
References: None available
Image Credits: Credit: American College of Surgeons

Keywords: Cancer, Mortality rates, Cancer screening, Appalachian health disparities, Public health initiatives, Preventive care.